Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
John McGrane
Observed names:
J. McGrane,
John Mcgrane
Institutions:
Royal Cornwall Hospital Trust,
Royal Cornwall Hospital
Observed institutions:
Royal Cornwall Hospital Trust,
Royal Cornwall Hospital
OpenAlex ID:
A5068771369
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
2026
·
Nicoletta Colombo
, Emese Zsiros
, et al.
·
The Lancet
·
83
Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations
2026
·
Sara Elena Rebuzzi
, Aruni Ghose
, et al.
·
The Oncologist
·
4
Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: A UK Multi-Centre Retrospective Study
2026
·
Benjamin Thomas Crosby
, Steffanie Winsor
, et al.
·
Clinical Genitourinary Cancer
·
2
Sovereign AI supercomputers: a global landscape review of unprecedented biomedical research infrastructure
2026
·
Lansaol Yang
, Michael E. Bryan
, et al.
·
Frontiers in Artificial Intelligence
·
1
PDF
Erratum to “Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review”. [Cancer Treat. Rev. 140 (2025) 103024]
2026
·
Natalie Charnley
, Kate Fife
, et al.
·
Cancer Treatment Reviews
·
1
PDF
Patient-reported outcomes from ENGOT-ov65/KEYNOTE-B96: a phase 3, randomized, double-blind study of pembrolizumab vs placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer
2026
·
Emese Zsiros
, Rutie Yin
, et al.
·
International Journal of Gynecological Cancer
·
1
Fern-EC-01 (BNT323-01): A phase 3 trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in patients with previously treated, HER2-expressing, recurrent endometrial cancer (EC).
2026
·
Floor Jenniskens Backes
, John McGrane
, et al.
·
Journal of Clinical Oncology
PDF
Patient-reported outcomes from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab versus placebo plus paclitaxel, with or without bevacizumab, in platinum-resistant recurrent ovarian cancer
2026
·
Emese Zsiros
, Rutie Yin
, et al.
·
Gynecologic Oncology
Extended multi-centre review of adjuvant pembrolizumab for renal cell carcinoma.
2026
·
Eleanor McCarthy
, Janet Brown
, et al.
·
Journal of Clinical Oncology
PDF
A Survey of Oncologists’ Perceptions and Opinions Regarding Brain Imaging in Metastatic Renal Cell Carcinoma Within the UK
2026
·
Ben T Crosby
, Emmanuel Eloebhose
, et al.
·
Cureus
PDF
BNT323-01: A phase 3 trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC)
2026
·
Hanna Dahlstrand
, Jae-Hoon Kim
, et al.
·
International Journal of Gynecological Cancer
663TiP BNT323-01: A phase III trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC)
2025
·
J-H. Kim
, H. Dahlstrand
, et al.
·
Annals of Oncology
Retrospective Real-world Evaluation of Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) during the COVID-19 Pandemic Compared to Docetaxel in mHSPC Pre-COVID-19
2023
·
A. Gould
, A. Muse
, et al.
·
Clinical Oncology
PDF
Show more works
View as search
Works count:
13
Citation count:
92
H-index:
2
I10-index:
1
Year
Topic
Type